Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple cancers.
Under the terms of the agreement, the two partners will jointly conduct pre-clinical and clinical trials to examine the efficacy of Pfizer’s proprietary investigational immunotherapy agents.
The agreement enables the partners to study the three immunotherapy agents in combination with standard therapies such as chemotherapy, radiation and targeted therapies to treat a range of cancers.
Peakdale Molecular has made an agreement with Metrion Biosciences to create drug discovery programmes for the customers for ion channel targets.
The agreement enables the two partners to offer integrated drug discovery services to pharmaceutical and biotechnology companies.
Selexis and OSE Immunotherapeutics have entered an contract to further develop immunotherapy agents targeting cancer and autoimmune diseases.
According to the agreement, Selexis’ proprietary SURE technology platform will be utilised to access performance research cell banks (RBCs) and advance the development of OSE Immunotherapuetics’ pre-clinical products.
Pfizer plans to raise gross proceeds of $1.25bn through the public offering of 4.125% notes due 2046.
Skadden, Aprs, Slate, Meagher & Flom is acting as the legal adviser for the offering.
Pfizer plans to use the funds to purchase the tender notes, for general corporate purposes and also to repay its outstanding commercial paper.
Tonghua Golden Horse Pharmaceutical Industry plans for the public offering of bonds. The company expects to raise up to $219m from the offering.
Image: Pfizer Inc plans to raise gross proceeds of $1.25bn through the public offering of 4.125% notes.
